Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4)

Publisher： Karger

E-ISSN： 1660-3818|44|5|351-357

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.44, Iss.5, 2017-08, pp. : 351-357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 1, 2018-01 ,pp. : 39-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cellular Stress Induced by Plasma-Derived Factor VIII Products

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 2, 2014-02 ,pp. : 140-144

Karger

Access to resources Recommend Favorite

Prospective, observational study of plasma‐derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : e122-e124

John Wiley & Sons Inc

Access to resources Recommend Favorite

Allergic reaction in a cohort of haemophilia A patients using plasma‐derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII

By  

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e281-e285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of platelet‐derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 12, 2015-12 ,pp. : 2210-2219

John Wiley & Sons Inc

Access to resources Recommend Favorite